Market closedNon-fractional

Amicus Therapeutics/FOLD

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Amicus Therapeutics

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Ticker

FOLD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Princeton, United States

Employees

517

FOLD Metrics

BasicAdvanced
$2.9B
Market cap
-
P/E ratio
-$0.49
EPS
0.79
Beta
-
Dividend rate
$2.9B
0.79
3.035
2.224
333.774
340.101
-1.14%
-5.08%
-126.10%
6.93
22.34
-33.64
-33.35
25.74%
-30.15%
16.66%
-20.24%

What the Analysts think about FOLD

Analyst Ratings

Majority rating from 12 analysts.
Buy

FOLD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-43.84% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$110M
-4.00%
Net income
-$48M
43.20%
Profit margin
-43.84%
49.17%

FOLD Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 144.07%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.07
-$0.11
-$0.16
-
Expected
-$0.12
-$0.08
-$0.06
-$0.07
-$0.05
Surprise
21.62%
-7.35%
86.79%
144.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Amicus Therapeutics stock?

Amicus Therapeutics (FOLD) has a market cap of $2.9B as of July 04, 2024.

What is the P/E ratio for Amicus Therapeutics stock?

The price to earnings (P/E) ratio for Amicus Therapeutics (FOLD) stock is 0 as of July 04, 2024.

Does Amicus Therapeutics stock pay dividends?

No, Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Amicus Therapeutics dividend payment date?

Amicus Therapeutics (FOLD) stock does not pay dividends to its shareholders.

What is the beta indicator for Amicus Therapeutics?

Amicus Therapeutics (FOLD) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Amicus Therapeutics stock

Buy or sell Amicus Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing